Exenatide PBS listing expanded

The PBS has listed GLP-1 inhibitor exenatide as an add-on therapy to insulin plus metformin for patients with type 2 diabetes.

Marketed as Byetta, exenatide is already PBS listed for patients with type 2 diabetes who are taking metformin, a sulfonylurea or a combination of both but are not achieving adequate glycaemic control.

Patients must have a HbA1c measurement of greater than 7% before starting